Bayer's Weinand Slams Silo Thinking, Short-Termism In Medicines Valuation
Executive Summary
Healthcare decision makers need to get out of their short-termist, siloed thinking when it comes to medicines reimbursement if healthcare systems are to remain sustainable, argued Bayer Pharma chief Dieter Weinand at the company's annual pharma media day.
You may also be interested in...
Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue
Bayer is combining its research and development organization in one unit. Discovery head Andreas Busch is leaving to join Shire while development head Joerg Moeller takes overall control. Meanwhile, Xofigo was linked to more fractures and deaths than the control arm in a prostate cancer trial.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.